Literature DB >> 24334122

A patient with partial trisomy 21 and 7q deletion expresses mild Down syndrome phenotype.

I Papoulidis1, E Papageorgiou1, E Siomou1, E Oikonomidou1, L Thomaidis2, A Vetro3, O Zuffardi4, T Liehr5, E Manolakos1, Papadopoulos Vassilis6.   

Abstract

BACKGROUND: Down syndrome (DS) is the most common aneuploidy in live-born individuals and it is well recognized with various phenotypic expressions. Although an extra chromosome 21 is the genetic cause for DS, specific phenotypic features may result from the duplication of smaller regions of the chromosome and more studies need to define genotypic and phenotypic correlations. CASE REPORT: We report on a 26 year old male with partial trisomy 21 presenting mild clinical symptoms relative to DS including borderline intellectual disability. In particular, the face and the presence of hypotonia and keratoconus were suggestive for the DS although the condition remained unnoticed until his adult age array comparative genomic hybridization (aCGH) revealed a 10.1 Mb duplication in 21q22.13q22.3 and a small deletion of 2.2 Mb on chromosomal band 7q36 arising from a paternal translocation t(7;21). The 21q duplication encompasses the gene DYRK1.
CONCLUSION: Our data support the evidence of specific regions on distal 21q whose duplication results in phenotypes recalling the typical DS face. Although the duplication region contains DYRK1, which has previously been implicated in the causation of DS, our patient has a borderline IQ confirming that their duplication is not sufficient to cause the full DS phenotype.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APP; Array comparative genome hybridization (aCGH); Chromosome 21; DNAJB6; DSCR1; DYRK1; DYRK1A; DnaJ/HSP40 homolog subfamily B member 6; Down syndrome; Down syndrome critical region gene 1; MX1; NCAPG2; OMIM; Online Mendelian Inheritance in Man; PTPRN2; Partial trisomy 21q; Phenotype; UBE3C; VIPR2; WD repeat-containing protein 60; WDR60; amyloid beta (A4) precursor protein; condensin-2 complex subunit G2; dual-specifity tyrosine phosphorylation-regulated kinase 1; dual-specifity tyrosine phosphorylation-regulated kinase 1A; myxovirus resistance 1, mouse, homolog of; tyrosine-protein phosphatase non-receptor type 2; ubiquitin protein ligase E3C; vasoactive intestinal peptide receptor 2

Mesh:

Year:  2013        PMID: 24334122     DOI: 10.1016/j.gene.2013.11.078

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  14 in total

1.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 2.  Genetics in Keratoconus: where are we?

Authors:  Yelena Bykhovskaya; Benjamin Margines; Yaron S Rabinowitz
Journal:  Eye Vis (Lond)       Date:  2016-06-27

Review 3.  Aneuploidy: a common and early evidence-based biomarker for carcinogens and reproductive toxicants.

Authors:  Daniele Mandrioli; Fiorella Belpoggi; Ellen K Silbergeld; Melissa J Perry
Journal:  Environ Health       Date:  2016-10-12       Impact factor: 5.984

4.  Excitatory and Inhibitory Neurons in the Hippocampus Exhibit Molecularly Distinct Large Dense Core Vesicles.

Authors:  José J Ramírez-Franco; Francisco J Munoz-Cuevas; Rafael Luján; Sandra Jurado
Journal:  Front Cell Neurosci       Date:  2016-08-31       Impact factor: 5.505

5.  A de novo 2.78-Mb duplication on chromosome 21q22.11 implicates candidate genes in the partial trisomy 21 phenotype.

Authors:  James D Weisfeld-Adams; Amanda K Tkachuk; Kenneth N Maclean; Naomi L Meeks; Stuart A Scott
Journal:  NPJ Genom Med       Date:  2016-03-02       Impact factor: 8.617

6.  Systematic reanalysis of partial trisomy 21 cases with or without Down syndrome suggests a small region on 21q22.13 as critical to the phenotype.

Authors:  Maria Chiara Pelleri; Elena Cicchini; Chiara Locatelli; Lorenza Vitale; Maria Caracausi; Allison Piovesan; Alessandro Rocca; Giulia Poletti; Marco Seri; Pierluigi Strippoli; Guido Cocchi
Journal:  Hum Mol Genet       Date:  2016-04-22       Impact factor: 6.150

Review 7.  Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.

Authors:  Megan Stringer; Charles R Goodlett; Randall J Roper
Journal:  Mol Genet Genomic Med       Date:  2017-09-20       Impact factor: 2.183

8.  Partial trisomy 21 map: Ten cases further supporting the highly restricted Down syndrome critical region (HR-DSCR) on human chromosome 21.

Authors:  Maria Chiara Pelleri; Elena Cicchini; Michael B Petersen; Lisbeth Tranebjaerg; Teresa Mattina; Pamela Magini; Francesca Antonaros; Maria Caracausi; Lorenza Vitale; Chiara Locatelli; Marco Seri; Pierluigi Strippoli; Allison Piovesan; Guido Cocchi
Journal:  Mol Genet Genomic Med       Date:  2019-06-25       Impact factor: 2.183

9.  Relationship between Apgar scores and long-term cognitive outcomes in individuals with Down syndrome.

Authors:  Laura Del Hoyo Soriano; Tracie C Rosser; Debra R Hamilton; Danielle J Harvey; Leonard Abbeduto; Stephanie L Sherman
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

Review 10.  Pathogenesis of Keratoconus: The intriguing therapeutic potential of Prolactin-inducible protein.

Authors:  Rabab Sharif; Sashia Bak-Nielsen; Jesper Hjortdal; Dimitrios Karamichos
Journal:  Prog Retin Eye Res       Date:  2018-07-13       Impact factor: 19.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.